Skip Main Navigation
Page Content

Save This Event

Event Saved

Who's Who in 2018: Where will we go in Healthcare Investing?

JLABS @ Toronto

Wednesday, April 11, 2018 from 10:00 AM to 1:00 PM (EDT)

Who's Who in 2018: Where will we go in Healthcare...

Ticket Information

Ticket Type Sales End Price * Fee Quantity
General Public   more info Apr 10, 2018 CA$25.00 CA$2.70
Student/Academic Apr 10, 2018 CA$15.00 CA$1.90
Media/Press   more info Apr 4, 2018 Free CA$0.00
Volunteer   more info Apr 2, 2018 Free CA$0.00
* Prices include GST/HST

Share Who's Who in 2018: Where will we go in Healthcare Investing?

Event Details

In 2017 we saw a banner year for healthcare investments, driven in part by advancements in artificial intelligence and machine learning for healthcare applications and a surge in Series A investments. With 2017 in the review mirror, Skip Kelly will take a look at – and makes sense of – the past trends to provide an informed view into what’s to come in 2018. As the investment market takes shape for the year, what can we expect for the IPO and M&A markets?

Join us during Health Innovation Week on Wednesday April 11th, as Skip shares his expertise and will provide insight into:

  • How the 2017 healthcare landscape compared to previous years
  • Current and total healthcare and sector investments
  • Which Biopharma indications attracted the most funds
  • Which venture firms are most active
  • Changes in the past crossover phenomenon
  • Exits: the trends in IPOs and M&A's

Following Skip’s insights into 2018, join us for an informative panel discussion on who is investing & where, and the type of deals and exits that are likely to be executed.

Speaker:
Skip Kelly | Head of Northeast Life Science and Healthcare, Silicon Valley Bank read bio»

Panelists:
Sam Ifergan | Managing Partner, iGan Partners (Rowanwood Ventures) read bio»
Stefan Larson | Venture Partner, Versant Ventures read bio»
Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Innovation, JJDC read bio»

Agenda:
10:00 AM | Registration Opens, Networking
10:30 AM | SVB Presentation
11:00 AM | Panel Discussion
12:00 PM | Networking Lunch
1:00 PM | Program Close

Fees:
$25 | General Public
$15 | Student/Academic
$35 | At the door

Location:
JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, ON

Speakers' Biographies:
Skip Kelly | Head of Northeast Life Science and Healthcare, Silicon Valley Bank
As a Managing Director in the Boston office, Skip leads the Northeast Life Science and Healthcare team covering the Biotechnology, Diagnostics, Medical Device and Healthcare IT sectors. At SVB since 2004 Skip has worked in a number of different roles including SVB's growth-stage VC/Technology lending group, asset based lending, advisory services/restructuring and training for new global employees. Skip is a graduate of Boston College, where he earned his BS degree in Finance. After growing up in a family business in southern Maine, he and his wife (and their two kids) currently live just outside of Boston.
Connect with Skip:   Connect on LinkedIn


Sam Ifergan | Managing Partner, iGan Partners (Rowanwood Ventures) 
Sam has over 20 years of entrepreneurial, technology and venture capital experience. As Managing Partner of the iGan Partners team, he is involved in the evaluation, structuring, execution, and monitoring of Rowanwood’s investments. Sam has been extensively involved with several companies, often serving as CEO, particularly in the early stages of each company’s development. Prior to founding iGan / Rowanwood Ventures, he co-founded several companies including Visualsonics, Tri-Link Technologies and Brighter Minds. Prior to that he was a strategy consultant with Mercer Management Consulting (now Oliver Wyman) where he advised Fortune 500 companies on corporate strategy. Sam has also held general management roles at NCR, where he led the deployment of enterprise-grade information technology systems.
Sam holds an MBA from the John Molson School of Business and a Bachelor of Electrical Engineering from McGill University.
Connect with Sam:   Connect on LinkedIn


Stefan Larson | Venture Partner, Versant Ventures
Stefan Larson is a Venture Partner and serves on the board of Northern Biologics, a Versant portfolio company. Based in the MaRS Discovery District, Stefan was the founding CEO of Blueline Bioscience, a Versant Discovery Engine, and was the founding CEO of Northern Biologics.
Stefan joined Versant after spending three years as the co-founder and CEO of Tornado Medical Systems, a revenue stage medical imaging and spectroscopy company. He previously held the position of Associate Principal with McKinsey & Company, serving global clients in healthcare and technology. He is currently a director of the MaRS Discovery District and Ontario Bioscience Innovation Organization (OBIO), and is a recipient of the Arbor Award for Exceptional Volunteer Service to the University of Toronto.
Stefan received his B.Sc. in Biology from McGill University, and his M.Sc. in Molecular and Medical Genetics from the University of Toronto. He completed his Ph.D. in Biophysics at Stanford University, where he helped build and launch Folding@home, the world’s most successful scientific public distributed computing platform.
Connect with Stefan:   Connect on LinkedIn


Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Innovation, JJDC
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc. and is based in Boston. She focuses on pharmaceutical investments in East Coast companies that are in areas of strategic interest to Johnson & Johnson. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Rodin Therapeutics, and Padlock Therapeutics and currently sits on the Board of Navitor Pharmaceuticals, PhaseBio Pharmaceuticals and the New England Venture Capital Association
Connect with Marian:   Connect on LinkedIn



Have questions about Who's Who in 2018: Where will we go in Healthcare Investing?? Contact JLABS @ Toronto

Save This Event

Event Saved

When & Where


JLABS @ Toronto
661 University Ave
Suite 1300
Toronto, ON M5G 1M1
Canada

Wednesday, April 11, 2018 from 10:00 AM to 1:00 PM (EDT)


  Add to my calendar

Organizer

JLABS @ Toronto

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to eight locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto and a ninth location, New York City, launching in 2018. For more information please visit jlabs.jnjinnovation.com.

  Contact the Organizer
Who's Who in 2018: Where will we go in Healthcare Investing?
Things to do in Toronto Networking Business

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.